Table 3.
Number of patients with HER2-targeted therapies and combined chemotherapies after enrollment. Number of patients with progression of disease (PD) under anti-HER2 therapy
| Anti-HER2 therapy | Chemotherapy | HER2 therapy n |
New HER2 therapy n |
|
|---|---|---|---|---|
| Trastuzumab | Docetaxel/Eribulin/Vinorelbin/ Paclitaxel/nab-Paclitaxel | Total | 12 | 3 |
| PD | 3 | 0 | ||
| Trastuzumab + Pertuzumab | Docetaxel/Paclitaxel/ Vinorelbin | Total | 3 | 5 |
| PD | 0 | 0 | ||
| Trastuzumab + Pertuzumab | No | Total | 0 | 1 |
| PD | 0 | 0 | ||
| Trastuzumab + Lapatinib | No | Total | 3 | 0 |
| PD | 0 | 0 | ||
| T-DM1 | No | Total | 4 | 4 |
| PD | 4 | 2 | ||
| Lapatinib | Capecitabin/ MTX + Cyclophosphamid | Total | 6 | 0 |
| PD | 3 | 0 | ||
| Pertuzumab | Paclitaxel | Total | 0 | 2 |
| PD | 0 | 1 |